Submitted by web@researchtop... on Tue, 07/27/2010 - 17:59
NCIC CTG BR.19: Gefitinib Therapy for Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC)
| CME test | Downloadable PDF | PowerPoint slides | CME Information and Faculty Disclosures |
| Read Dr Love's original email (from July 29, 2010) | Subscribe to Dr Love's email alerts | ||
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Roy S Herbst, MD, PhD (6/23/10) and Lecia V Sequist, MD, MPH (6/18/10)
Goss GD et al. A Phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor inhibitor gefitinib in completely resected Stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. Proc ASCO 2010;Abstract LBA7005.